{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:45:19Z","timestamp":1794876319794,"version":"4.9.1"},"reference-count":131,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research"},{"name":"Canadian Cancer Society"},{"name":"Leukemia &amp; Lymphoma Society of Canada"},{"name":"Collings Stevens Chronic Leukemia Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic myeloid leukemia is a multistep, multi-lineage myeloproliferative disease that originates from a translocation event between chromosome 9 and chromosome 22 within the hematopoietic stem cell compartment. The resultant fusion protein BCR::ABL1 is a constitutively active tyrosine kinase that can phosphorylate multiple downstream signaling molecules to promote cellular survival and inhibit apoptosis. Currently, tyrosine kinase inhibitors (TKIs), which impair ABL1 kinase activity by preventing ATP entry, are widely used as a successful therapeutic in CML treatment. However, disease relapses and the emergence of resistant clones have become a critical issue for CML therapeutics. Two main reasons behind the persisting obstacles to treatment are the acquired mutations in the ABL1 kinase domain and the presence of quiescent CML leukemia stem cells (LSCs) in the bone marrow, both of which can confer resistance to TKI therapy. In this article, we systemically review the structural and molecular properties of the critical domains of BCR::ABL1 and how understanding the essential role of BCR::ABL1 kinase activity has provided a solid foundation for the successful development of molecularly targeted therapy in CML. Comparison of responses and resistance to multiple BCR::ABL1 TKIs in clinical studies and current combination treatment strategies are also extensively discussed in this article.<\/jats:p>","DOI":"10.3390\/ijms25063307","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T09:32:30Z","timestamp":1710495150000},"page":"3307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia"],"prefix":"10.3390","volume":"25","author":[{"given":"Andrew","family":"Wu","sequence":"first","affiliation":[{"name":"Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Liu","sequence":"additional","affiliation":[{"name":"Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Fruhstorfer","sequence":"additional","affiliation":[{"name":"Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7340","authenticated-orcid":false,"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy, and Monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL Genes and Leukemic Phenotype: From Molecular Mechanisms to Clinical Correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet Laboratory Recommendations for the Diagnosis and Management of Chronic Myeloid Leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and Management of Accelerated and Blast Phases of Chronic Myeloid Leukemia","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.13184","article-title":"Long-Term Outcome of Chronic Myeloid Leukaemia Patients with P210 and P190 Co-Expression at Baseline","volume":"169","author":"Molica","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-01082-4","article-title":"Characterization of P190-Bcr-Abl Chronic Myeloid Leukemia Reveals Specific Signaling Pathways and Therapeutic Targets","volume":"35","author":"Kim","year":"2021","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-Chronic Myeloid Leukemia: Low Levels of P230 BCR\/ABL mRNA and Undetectable BCR\/ABL Protein May Predict an Indolent Course","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of Chronic Myeloid Leukemia in 2023\u2014Common Ground and Common Sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, Quiescent, Philadelphia-Positive Stem Cells from Patients with Chronic Myeloid Leukemia Are Insensitive to STI571 in Vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic Myeloid Leukemia Stem Cells Possess Multiple Unique Features of Resistance to BCR-ABL Targeted Therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human Chronic Myeloid Leukemia Stem Cells Are Insensitive to Imatinib despite Inhibition of BCR-ABL Activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The Chronic Myeloid Leukemia Stem Cell: Stemming the Tide of Persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhai, X., and Jiang, X. (2022). Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081841"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing Chronic Myeloid Leukemia for Treatment-Free Remission: A Proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the C-Abl and Bcr\u2013Abl Tyrosine Kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural Basis for the Autoinhibition of C-Abl Tyrosine Kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, Present, and Future of Bcr-Abl Inhibitors: From Chemical Development to Clinical Efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/jacs.7b12430","article-title":"ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation","volume":"140","author":"Sonti","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"ref_23","first-page":"4236","article-title":"Crystal Structures of the Kinase Domain of C-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The Ins and Outs of Bcr-Abl Inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-08-3953","article-title":"Equally Potent Inhibition of C-Src and Abl by Compounds That Recognize Inactive Kinase Conformations","volume":"69","author":"Seeliger","year":"2009","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Levinson, N.M., Kuchment, O., Shen, K., Young, M.A., Koldobskiy, M., Karplus, M., Cole, P.A., and Kuriyan, J. (2006). A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain. PLoS Biol., 4.","DOI":"10.2210\/pdb2g1t\/pdb"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.str.2007.01.015","article-title":"C-Src Binds to the Cancer Drug Imatinib with an Inactive Abl\/c-Kit Conformation and a Distributed Thermodynamic Penalty","volume":"15","author":"Seeliger","year":"2007","journal-title":"Structure"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.molcel.2006.01.035","article-title":"Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase","volume":"21","author":"Nagar","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and Dynamic Regulation of Abl Kinases*","volume":"288","author":"Panjarian","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A Myristoyl\/Phosphotyrosine Switch Regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The Allosteric Inhibitor ABL001 Enables Dual Targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_37","first-page":"7587","article-title":"A Coiled-Coil Oligomerization Domain of Bcr Is Essential for the Transforming Function of Bcr-Abl Oncoproteins","volume":"13","author":"McWhirter","year":"1993","journal-title":"Mol. Cell. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V96.2.664","article-title":"The Grb2 Binding Site Is Required for the Induction of Chronic Myeloid Leukemia-like Disease in Mice by the Bcr\/Abl Tyrosine Kinase","volume":"96","author":"Million","year":"2000","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the Molecular Network of the Drug Target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","article-title":"The Coiled-Coil Domain and Tyr177 of Bcr Are Required to Induce a Murine Chronic Myelogenous Leukemia-like Disease by Bcr\/Abl","volume":"99","author":"He","year":"2002","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Xie, T., Saleh, T., Rossi, P., Miller, D., and Kalodimos, C.G. (2022). Imatinib Can Act as an Allosteric Activator of Abl Kinase. J. Mol. Biol., 434.","DOI":"10.1016\/j.jmb.2021.167349"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia","volume":"63","author":"Fendrich","year":"2007","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of Tyrosine Kinases by Mutation of the Gatekeeper Threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 Kinase Domain-Mediated Resistance in Chronic Myeloid Leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of Resistance to ABL Kinase Inhibition in CML and the Development of next Generation ABL Kinase Inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In Vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants","volume":"65","author":"Walters","year":"2005","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00432-013-1488-z","article-title":"The Development of Dasatinib as a Treatment for Chronic Myeloid Leukemia (CML): From Initial Studies to Application in Newly Diagnosed Patients","volume":"139","author":"Hochhaus","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib\/Nilotinib and Dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1747-0285.2009.00905.x","article-title":"Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template","volume":"75","author":"Zhou","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Levinson, N.M., and Boxer, S.G. (2012). Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029828"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The Specificity of Asciminib, a Potential Treatment for Chronic Myeloid Leukemia, as a Myristate-Pocket Binding ABL Inhibitor and Analysis of Its Interactions with Mutant Forms of BCR-ABL1 Kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-20-0069","article-title":"Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer","volume":"19","author":"Jones","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1182\/blood-2023-188135","article-title":"Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib","volume":"142","author":"Han","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib Effectively Inhibits BCR-ABL1(T315I) with a Distinct Binding Conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-015-0190-9","article-title":"Anti-Leukemic Activity of Axitinib against Cells Harboring the BCR-ABL T315I Point Mutation","volume":"8","author":"Okabe","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lindstr\u00f6m, H.J.G., and Friedman, R. (2020). The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: An Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06782-9"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2016.152710","article-title":"Phase 1 Dose-Finding Study of Rebastinib (DCC-2036) in Patients with Relapsed Chronic Myeloid Leukemia and Acute Myeloid Leukemia","volume":"102","author":"Cortes","year":"2017","journal-title":"Haematologica"},{"key":"ref_67","first-page":"686","article-title":"Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"17","author":"Molica","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.11477","article-title":"Sudden Onset of the Blastic Phase of Chronic Myelogenous Leukemia: Patterns and Implications","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/10428194.2011.652108","article-title":"Long-Term Follow-up of Patients with Chronic Myeloid Leukemia in Chronic Phase Developing Sudden Blast Phase on Imatinib Therapy","volume":"53","author":"Tantiworawit","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-Free Remission Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: Results from the ENESTfreedom Study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-Free Remission Following Frontline Nilotinib in Patients with Chronic Phase Chronic Myeloid Leukemia: 5-Year Update of the ENESTfreedom Trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood-2022-167764","article-title":"Long-Term Follow-up of Low-Dose Dasatinib (50 mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia","volume":"140","author":"Haddad","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-Dose Dasatinib 50 mg\/day versus Standard-Dose Dasatinib 100 mg\/day as Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-Term Follow-up of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e2486","DOI":"10.1097\/MD.0000000000002486","article-title":"Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients","volume":"95","author":"Qin","year":"2016","journal-title":"Medicine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/s41375-023-02062-0","article-title":"Identification of Multivariable microRNA and Clinical Biomarker Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis","volume":"37","author":"Wu","year":"2023","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 Transcript Levels at 3 and 6 Months in Chronic Myeloid Leukemia: Implications for Early Intervention Strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ddr.21266","article-title":"miRNAs as Biomarkers in Chronic Myelogenous Leukemia","volume":"76","author":"Kotagama","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1038\/s41598-018-29923-4","article-title":"Quantitative Prediction of Long-Term Molecular Response in TKI-Treated CML\u2014Lessons from an Imatinib versus Dasatinib Comparison","volume":"8","author":"Glauche","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","article-title":"MicroRNA Signature Refine Response Prediction in CML","volume":"9","author":"Alves","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3389\/fonc.2020.01544","article-title":"Comparison of microRNA Expression Profile in Chronic Myeloid Leukemia Patients Newly Diagnosed and Treated by Allogeneic Hematopoietic Stem Cell Transplantation","volume":"10","author":"Martins","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional Chromosomal Abnormalities at Chronic Myeloid Leukemia Diagnosis Predict an Increased Risk of Progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41375-022-01680-4","article-title":"Identification of Key microRNAs as Predictive Biomarkers of Nilotinib Response in Chronic Myeloid Leukemia: A Sub-Analysis of the ENESTxtnd Clinical Trial","volume":"36","author":"Yen","year":"2022","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs. Bosutinib in CML after 2 or More Prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after Failure of Second-Generation Tyrosine Kinase Inhibitor in Resistant Chronic-Phase Chronic Myeloid Leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2022000328","article-title":"Management of TKI-Resistant Chronic Phase CML","volume":"2022","author":"Hughes","year":"2022","journal-title":"Hematology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106337","DOI":"10.1016\/j.leukres.2020.106337","article-title":"Novel Therapeutic Approaches in Chronic Myeloid Leukemia","volume":"91","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: The First-in-Class Allosteric Inhibitor of BCR::ABL1 Kinase","volume":"58","author":"Choi","year":"2023","journal-title":"Blood Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1182\/blood-2022-162249","article-title":"ASC4FIRST: A Phase III Study of Asciminib vs. Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","volume":"140","author":"Hughes","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2217\/fon-2022-0923","article-title":"Asciminib Monotherapy for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: The ASC4FIRST Phase III Trial","volume":"18","author":"Cortes","year":"2022","journal-title":"Future Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1182\/blood-2022-167044","article-title":"ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)","volume":"140","author":"Sasaki","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome\u2013Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2021.39.15_suppl.7000","article-title":"OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)","volume":"39","author":"Cortes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2022-157822","article-title":"Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","volume":"140","author":"Cortes","year":"2022","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and OPTIC Trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2022-170773","article-title":"A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)","volume":"140","author":"Senapati","year":"2022","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO-SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non-Randomised, Trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjh.16408","article-title":"Risk of Molecular Recurrence after Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukaemia Patients: A Systematic Review of Literature with a Meta-Analysis of Studies over the Last Ten Years","volume":"189","author":"Dulucq","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","article-title":"Molecular Status 36 Months after TKI Discontinuation in CML Is Highly Predictive for Subsequent Loss of MMR-Final Report from AFTER-SKI","volume":"35","author":"Richter","year":"2021","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late Molecular Recurrences in Patients with Chronic Myeloid Leukemia Experiencing Treatment-Free Remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/bjh.18796","article-title":"Efficacy and Safety of Nilotinib in Chronic Myeloid Leukaemia Patients Who Failed to Achieve a Treatment-Free Remission Period after Imatinib Discontinuation: Results of the French Nilo Post-STIM Study","volume":"201","author":"Dulucq","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Flygt, H., S\u00f6derlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., and Majeed, W. (2024). Treatment-Free Remission after a Second TKI Discontinuation Attempt in Patients with Chronic Myeloid Leukemia Re-Treated with Dasatinib\u2014Interim Results from the DAstop2 Trial. Leukemia, 1\u20137.","DOI":"10.1038\/s41375-024-02145-6"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2023-187740","article-title":"Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a Well-Tolerated and Effective Tyrosine Kinase Inhibitor for Patients with T315I-Mutated Chronic Myeloid Leukemia: Results of an Open-Label, Multicenter Phase 1\/2 Trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1065130","DOI":"10.3389\/fphar.2022.1065130","article-title":"Potential Drug-Drug Interaction of Olverembatinib (HQP1351) Using Physiologically Based Pharmacokinetic Models","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2022-162387","article-title":"Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2022-170868","article-title":"A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China","volume":"140","author":"Jiang","year":"2022","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2022-170698","article-title":"Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation","volume":"140","author":"Jiang","year":"2022","journal-title":"Blood"},{"key":"ref_120","first-page":"5","article-title":"Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)","volume":"136","author":"Lu","year":"2020","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood-2023-187744","article-title":"Update of Olverembatinib (HQP1351) Overcoming Ponatinib and\/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2023-184421","article-title":"Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study","volume":"142","author":"Gong","year":"2023","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.tranon.2020.100766","article-title":"GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 Inhibitor Against Leukemia In Vitro and In Vivo","volume":"13","author":"Wang","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11010-022-04576-0","article-title":"Developing Therapeutic Approaches for Chronic Myeloid Leukemia: A Review","volume":"478","author":"Kumar","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Sadaf, S., Awasthi, D., Singh, A.K., Nagarkoti, S., Kumar, S., Barthwal, M.K., and Dikshit, M. (2020). Pyroptotic and Apoptotic Cell Death in iNOS and nNOS Overexpressing K562 Cells: A Mechanistic Insight. Biochem. Pharmacol., 176.","DOI":"10.1016\/j.bcp.2019.113779"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"26027","DOI":"10.18632\/oncotarget.15215","article-title":"The CRISPR\/Cas9 System Efficiently Reverts the Tumorigenic Ability of BCR\/ABL in Vitro and in a Xenograft Model of Chronic Myeloid Leukemia","volume":"8","author":"Benito","year":"2017","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Vuelta, E., Ordo\u00f1ez, J.L., Sanz, D.J., Ballesteros, S., Hern\u00e1ndez-Rivas, J.M., M\u00e9ndez-S\u00e1nchez, L., S\u00e1nchez-Mart\u00edn, M., and Garc\u00eda-Tu\u00f1\u00f3n, I. (2022). CRISPR\/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR\/ABL Leukemic Cells in CML. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202205.0008.v1"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","article-title":"In Vivo CRISPR\/Cas9 Targeting of Fusion Oncogenes for Selective Elimination of Cancer Cells","volume":"11","author":"Martin","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Vuelta, E., Garc\u00eda-Tu\u00f1\u00f3n, I., Hern\u00e1ndez-Carabias, P., M\u00e9ndez, L., and S\u00e1nchez-Mart\u00edn, M. (2021). Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy. Biology, 10.","DOI":"10.20944\/preprints202101.0212.v1"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12967-022-03765-1","article-title":"Integration of CRISPR\/Cas9 with Artificial Intelligence for Improved Cancer Therapeutics","volume":"20","author":"Bhat","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tibtech.2016.06.008","article-title":"In Silico Meets In Vivo: Towards Computational CRISPR-Based sgRNA Design","volume":"35","author":"Chuai","year":"2017","journal-title":"Trends Biotechnol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:46Z","timestamp":1760105626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":131,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063307"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063307","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}